Trump’s USAID Cuts Halt Groundbreaking South African HIV Vaccine Trials

In a significant setback to global health research, U.S. President Donald Trump’s decision to dismantle the United States Agency for International Development (USAID) has led to the suspension of promising HIV vaccine trials in South Africa.

Nozipho Mlotshwa, a lab technician at the University of the Witwatersrand in Johannesburg, and her team were on the brink of advancing their HIV vaccine after positive results in animal tests. However, their work has been frozen, with their promising findings now sitting untouched in a freezer. The vaccine had shown an immune response in rabbits, but further trials were halted by USAID’s order to stop funding, leaving researchers and health professionals in limbo.

“This was very exciting. We were getting quite good results,” Mlotshwa shared in an interview with Reuters, reflecting the team’s disappointment. The halt has affected not only Mlotshwa’s project but also a separate HIV vaccine candidate trial set to begin human testing in South Africa, Kenya, and Uganda.

The trials, part of a larger initiative funded entirely by a $45 million USAID grant, aimed to develop a much-needed HIV vaccine. The freeze is a direct result of Trump’s controversial decision to cut back USAID funding, which has impacted various global health initiatives, including HIV treatment and research efforts in South Africa.

The suspension of these trials underscores the significant influence of U.S. foreign policy on scientific progress worldwide. Researchers, health advocates, and global health organizations are calling for a reevaluation of such decisions to ensure that essential programs, like those combating HIV/AIDS, continue to move forward.

This report is based on an interview conducted by Reuters.